RNA interference mediated inhibition of epithelial sodium channel (ENaC) gene expression using short interfering nucleic acid (siNA)

Details for Australian Patent Application No. 2009319949 (hide)

Owner Merck Sharp & Dohme Corp.

Inventors Pickering, Victoria; Strapps, Walter

Agent Spruson & Ferguson

Pub. Number AU-A-2009319949

PCT Pub. Number WO2010/062817

Priority 61/158,316 06.03.09 US; 61/118,144 26.11.08 US; 61/118,157 26.11.08 US; 61/118,150 26.11.08 US; 61/118,160 26.11.08 US

Filing date 18 November 2009

Wipo publication date 3 June 2010

International Classifications

C12N 15/113 (2010.01) Mutation or genetic engineering - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

A61K 31/713 (2006.01) - Double-stranded nucleic acids or oligonucleotides

Event Publications

30 June 2011 PCT application entered the National Phase

  PCT publication WO2010/062817 Priority application(s): WO2010/062817

4 October 2012 Alteration of Name

  The name of the applicant has been altered to Merck Sharp & Dohme Corp.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009319962-Nasal spray device

2009319947-Polypeptides for inducing a protective immune response against Staphylococcus aureus